VRAX logo

VRAX Stock Overview

Profile

Full Name:

Virax Biolabs Group Limited

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

July 21, 2022

Indexes:

Not included

Website:

http://viraxbiolabs.com

Description:

Virax Biolabs Group Limited (VRAX) focuses on developing innovative diagnostic solutions and treatments for viral infections. The company aims to improve global health by providing advanced technologies for early detection and management of diseases, particularly in the context of emerging viral threats.

Key Details

Price

$2.08

Market Cap

$9.03 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$156.40 K(+1718.60% YoY)

Annual EPS

-$3.36(+34.50% YoY)

PE Ratio

-

Annual ROE

-95.90%

Annual Debt To Equity

0.00

Beta

0.12

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 18, 2023

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with VRAX included

Growing Shares Outstanding
UK stocks
Stocks below SMA 200
Best performing stocks last 3 months
Healthcare sector
All stocks
High Altman Z score stocks
Biggest stock gainers today
Biotechnology industry
Small cap stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$2.08
VRAX price is $2.08

Price All-time High

$208.00
VRAX price is currently -99.00% below its historical high of $208.00

Price Analysts Target

-
VRAX price consensus analysts' forecast is unknown

Price Most Recent Change

+14.28%
VRAX price was up +14.28% on Feb 22, 2025

Price YTD Change

-7.49%
VRAX price is down -7.49% since January 1st

Price 3-Year Change

-
VRAX price 3-year change is unknown

Market cap

Market Cap

$9.03 M
VRAX market capitalization is $9.03 million

Market Cap 3-Year Change

-
VRAX market capitalization 3-year change is unknown

Market Cap All-time High

$236.58 M
VRAX market capitalization is currently -96.18% below its historical high of $236.58 million

Market Cap Sector Rank

17.07%
VRAX market capitalization is higher than 17.07% of companies in Healthcare sector

Technical

Beta

0.12
VRAX beta is 0.12

200-day SMA

$1.92
VRAX price is currently +8.46% above its 200-day simple moving average

14-day RSI

48.73
VRAX 14-day relative strength index is 48.73

30-day Relative Volume

0.78
VRAX 30-day relative volume is 0.78

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$156.40 K
VRAX annual revenue is $156.40 thousand

Annual Revenue Analysts Estimate

-
VRAX annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

+1718.6%
VRAX annual revenue is up +1718.6% year-on-year

Annual Revenue Sector Rank

6.03%
VRAX annual revenue is higher than 6.03% of companies in Healthcare sector

Profit

Annual Gross Profit

$50.60 K
VRAX annual gross profit is $50.60 thousand

Annual Gross Margin

32.34%
VRAX annual gross profit margin is 32.34%

Annual Operating Profit

-$6.11 M
VRAX annual operating income is -$6.11 million

Annual Operating Margin

-3903.69%
VRAX annual operating profit margin is -3903.69%

Annual Net Income

-$6.73 M
VRAX annual net profit is -$6.73 million

Annual Net Margin

-4304.81%
VRAX annual net profit margin is -4304.81%

EPS

Annual EPS

-$3.36
VRAX annual earnings per share is -$3.36

Annual EPS Analysts Estimate

-
VRAX annual earnings per share consensus analysts' forecast is unknown

Annual EPS 1-Year Change

+34.5%
VRAX annual earnings per share is up +34.5% year-on-year

Annual EPS Sector Rank

30.88%
VRAX annual earnings per share is higher than 30.88% of companies in Healthcare sector

ROA & ROE

Annual ROA

-88.04%
VRAX annual return on assets is -88.04%

Annual ROE

-95.90%
VRAX annual return on equity is -95.90%

EBIT & EBITDA

Annual EBIT

-$6.71 M
VRAX annual earnings before interest & taxes is -$6.71 million

Annual EBITDA

-$6.61 M
VRAX annual EBITDA is -$6.61 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
VRAX price to earnings ratio value is unknown

PE Ratio Sector Rank

-
VRAX price to earnings ratio is unknown

PB Ratio

PB Ratio

1.04
VRAX price to book ratio is 1.04

PB Ratio Sector Rank

42.42%
VRAX price to book ratio is higher than 42.42% of companies in Healthcare sector

PS Ratio

PS Ratio

-
VRAX price to sales ratio value is unknown

PS Ratio Sector Rank

-
VRAX price to sales ratio is unknown

Enterprise value

Enterprise Value

$2.13 M
VRAX enterprise value is $2.13 million

Enterprise Value Sector Rank

13.4%
VRAX enterprise value is higher than 13.4% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-
VRAX EV/EBITDA value is unknown

EV/EBITDA Sector Rank

-
VRAX EV/EBITDA is unknown

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

25.94
VRAX annual current ratio is 25.94

Annual Quick Ratio

25.59
VRAX annual quick ratio is 25.59

Leverage

Annual Debt To Equity

0.00
VRAX annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-249.52
VRAX annual interest coverage ratio is -249.52

Risk & Stability

Piotroski F-Score

-
VRAX piotroski f-score value is unknown

Altman Z-Score

7.88
VRAX altman z-score is 7.88

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$5.48 M
VRAX annual total assets is $5.48 million

Annual Non Current Assets

$1.10 M
VRAX annual long term assets is $1.10 million

Annual Current Assets

$4.38 M
VRAX annual total current assets is $4.38 million

Annual Cash & Cash Equivalents

$3.59 M
VRAX annual cash & cash equivalents is $3.59 million

Equity

Annual Book Value

$5.37 M
VRAX annual book value is $5.37 million

Annual Working Capital

$4.21 M
VRAX annual working capital is $4.21 million

Liabilities

Annual Total Liabilities

$345.20 K
VRAX annual total liabilities is $345.20 thousand

Annual Total Long Term Liabilities

$176.30 K
VRAX annual total long term liabilities is $176.30 thousand

Annual Current Liabilities

$168.80 K
VRAX annual total current liabilities is $168.80 thousand

Annual Accounts Payable

$45.60 K
VRAX annual accounts payable is $45.60 thousand

Debt

Annual Total Debt

$224.30 K
VRAX annual total debt is $224.30 thousand

Annual Total Debt 1-Year Change

+53.42%
VRAX annual total debt is up +53.42% year-on-year

Annual Long Term Debt

$176.30 K
VRAX annual long term debt is $176.30 thousand

Annual Short Term Debt

$48.00 K
VRAX annual short term debt is $48.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$6.26 M
VRAX annual total expenses is $6.26 million

Annual Operating Expenses

$6.16 M
VRAX annual total operating expenses is $6.16 million

Annual Cost Of Goods Sold

$105.80 K
VRAX annual cost of goods sold is $105.80 thousand

Annual SGA

$4.59 M
VRAX annual SGA is $4.59 million

Annual D&A

$103.10 K
VRAX annual depreciation & amortization is $103.10 thousand

Annual Interest Expense

$26.90 K
VRAX annual interest expense is $26.90 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$6.25 M
VRAX annual cash flow from operations is -$6.25 million

Annual CFO 1-Year Change

-49.46%
VRAX annual cash flow from operations is down -49.46% year-on-year

Annual CFI

-$1.16 M
VRAX annual cash flow from investing activities is -$1.16 million

Annual CFI 1-Year Change

-552.69%
VRAX annual cash flow from investing activities is down -552.69% year-on-year

Annual CFF

$1.65 M
VRAX annual cash flow from financing activities is $1.65 million

Annual CFF 1-Year Change

-87.96%
VRAX annual cash flow from financing activities is down -87.96% year-on-year

Free CashFlow

Annual FCF

-$7.41 M
VRAX annual free cash flow is -$7.41 million

Annual FCF 1-Year Change

-70.06%
VRAX annual free cash flow is down -70.06% year-on-year

CAPEX

Annual CAPEX

$1.16 M
VRAX annual capital expenditures is $1.16 million

Annual CAPEX 1-Year Change

+552.69%
VRAX annual capital expenditures is up +552.69% year-on-year

Institutional Ownership

Similar stocks

NURO logo
NeuroMetrix (NURO)
AEMD logo
Aethlon Medical (AEMD)
EVGN logo
Evogene (EVGN)
MHUA logo
Meihua International Medical Technologies Co (MHUA)
OMGA logo
Omega Therapeutics (OMGA)
ALUR logo
Allurion Technologies (ALUR)
CJJD logo
China Jo-Jo Drugstores (CJJD)
APDN logo
Applied DNA Sciences (APDN)
PAVM logo
PAVmed (PAVM)

FAQ

  • What is the ticker symbol for Virax Biolabs Group Limited?
  • Does Virax Biolabs Group Limited pay dividends?
  • What sector is Virax Biolabs Group Limited in?
  • What industry is Virax Biolabs Group Limited in?
  • What country is Virax Biolabs Group Limited based in?
  • When did Virax Biolabs Group Limited go public?
  • Is Virax Biolabs Group Limited in the S&P 500?
  • Is Virax Biolabs Group Limited in the NASDAQ 100?
  • Is Virax Biolabs Group Limited in the Dow Jones?
  • When does Virax Biolabs Group Limited report earnings?

What is the ticker symbol for Virax Biolabs Group Limited?

The ticker symbol for Virax Biolabs Group Limited is NASDAQ:VRAX

Does Virax Biolabs Group Limited pay dividends?

No, Virax Biolabs Group Limited does not pay dividends

What sector is Virax Biolabs Group Limited in?

Virax Biolabs Group Limited is in the Healthcare sector

What industry is Virax Biolabs Group Limited in?

Virax Biolabs Group Limited is in the Biotechnology industry

What country is Virax Biolabs Group Limited based in?

Virax Biolabs Group Limited is headquartered in United Kingdom

When did Virax Biolabs Group Limited go public?

Virax Biolabs Group Limited's initial public offering (IPO) was on July 21, 2022

Is Virax Biolabs Group Limited in the S&P 500?

No, Virax Biolabs Group Limited is not included in the S&P 500 index

Is Virax Biolabs Group Limited in the NASDAQ 100?

No, Virax Biolabs Group Limited is not included in the NASDAQ 100 index

Is Virax Biolabs Group Limited in the Dow Jones?

No, Virax Biolabs Group Limited is not included in the Dow Jones index

When does Virax Biolabs Group Limited report earnings?

The date for Virax Biolabs Group Limited's next earnings report has not been announced yet